Osteogenesis-related factor Runx2 expression in necrotic femoral head tissue: study protocol for a non-randomized, parallel-controlled trial

doi:10.3969/j.issn.2095-4344.2016.17.019

Abstract

Abstract:

BACKGROUND: Osteonecrosis of the femoral head (ONFH) results from an interruption of the blood supply to the femoral head or injury-caused death of chondrocytes and bone marrow components. Many osteogenesis-related factors, such as Runt-related transcription factor 2 (Runx2), bone morphogenetic protein (BMP), osteoprotegerin and osteocalcin, are involved in the subsequent repair process. The Runx2 gene has been shown to control osteoblast differentiation and formation by upregulating the transcription of various mineralization-related protein genes, allowing osteoblast precursors differentiation into osteoblasts, and playing a key role in bone repair.

METHODS/DESIGN: This retrospective, single-center, non-randomized, parallel-controlled trial was performed at Shengjing Hospital of China Medical University, China. Fifteen patients with ONFH and 15 patients with osteoarthritis undergoing total hip replacement were included. Primary measure was Runx2messenger RNA (mRNA) expression in femoral head and neck tissue, and secondary measures included BMP-2, BMP-7 and osteoprotegerin mRNA expression, as well as osteocalcin immunoreactivity. This trial was registered at ClinicalTrials.gov (identifier: NCT02735538) and acquired written approval from the Ethics Committee of Shengjing Hospital of China Medical University (approval No. 2016PS222K). Written informed consent was obtained from each included patient.

DISCUSSION: This study involved in the detection of mRNA expression of several bone repair-related genes, including Runx2, in the femoral head and neck of patients with ONFH was performed between 2010 and 2011. This observational study will help clarify the role and possible clinical significance of Runx2 in femoral head necrosis, bone repair and reconstruction.
中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程

Key words: Femur Head Necrosis, Osteoarthritis, Bone Morphogenetic Proteins, Osteoprotegerin, Osteocalcin

Yang Li-qing, Dong Cheng-jian, Zhu Shu. Osteogenesis-related factor Runx2 expression in necrotic femoral head tissue: study protocol for a non-randomized, parallel-controlled trial[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(17): 2569-2574.

References

[1] Xu J, Li Z, Hou Y, et al. Potential mechanisms underlying the Runx2 induced osteogenesis of bone marrow mesenchymal stem cells. Am J Transl Res. 2015;7(12):2527-2535.

[2] Zhang YL, Yin JH, Ding H, et al. Vitamin K2 Prevents Glucocorticoid-induced Osteonecrosis of the Femoral Head in Rats. Int J Biol Sci. 2016;12(4):347-358.

[3] Tan G, Kang PD, Pei FX, et al. Comparing study on expression levels of related factors in glucocorticoid- induced osteonecrosis of femoral head and hip osteoarthritis. Chin J Joint Surg. 2012;6:260-267.

[4] 王佰亮,李子荣,张念非.糖皮质激素性股骨头缺血坏死的发病机理与早期干预[J].中国矫形外科杂志, 2005, 13(24):1892-1894．

[5] Gao RT, Zhan LP, Meng C, et al. Homeobox B7 promotes the osteogenic differentiation potential of mesenchymal stem cells by activating RUNX2 and transcript of BSP. Int J Clin Exp Med. 2015;8(7): 10459-10470.

[6] Yu S, Geng Q, Pan Q, et al. MiR-690, a Runx2- targeted miRNA, regulates osteogenic differentiation of C2C12 myogenic progenitor cells by targeting NF-kappaB p65. Cell Biosci. 2016;6:10.

[7] Mishima K, Kitoh H, Ohkawara B, et al. Lansoprazole Upregulates Polyubiquitination of the TNF Receptor- Associated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis. EBioMedicine. 2015;2(12): 2046-2061.

[8] Zhang JY, Li LC. Genetic expression and functional characterization of the RUNX2 gene in human adult bone marrow mesenchymal stem cells. Genet Mol Res. 2015;14(4):18210-18217.

[9] Rojas A, Aguilar R, Henriquez B, et al. Epigenetic Control of the Bone-master Runx2 Gene during Osteoblast- lineage Commitment by the Histone Demethylase JARID1B/KDM5B.J Biol Chem.2015;290(47):28329- 28342.

[10] 许海甲,李章华,侯煜东,等.Micro-CT评价Runx2基因修饰的骨髓间充质干细胞静脉移植促进缺血性股骨头坏死兔坏死股骨头修复效果[J].生物技术通讯,2015,6(6): 825-829.

[11] Liu YW, Wang YH, Jiang YD, et al. Impacts on steroid- induced femoral head necrosis, serum osteocalcin and calcitonin treated with Gugutou Huaisi Yu Capsules in rabbits. World J Integr Tradit West Med. 2014;9(3): 248-250.

[12] Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol. 2010;7(12): 700-710．

[13] 杨俊兴,方斌,徐传毅,等.通络生骨胶囊对激素性股骨头坏死大鼠骨钙素、降钙素与骨密度的影响[J].广州中医药大学学报, 2007,24(1):41-43．

[14] 陈镇秋,何伟,魏秋实,等.激素性股骨头坏死患者骨组织中骨代谢相关因子的表达[J].中华关节外科杂志:电子版, 2015,9(2):183-187.

[15] 唐磊,张元和.骨形态发生蛋白在股骨头坏死治疗中的应用[J].中国组织工程研究与临床康复,2010,14(46): 8665-8668.

[16] Ma XW, Cui DP, Zhao DW. Vascular endothelial growth factor/bone morphogenetic protein-2 bone marrow combined modification of the mesenchymal stem cells to repair the avascular necrosis of the femoral head. Int J Clin Exp Med. 2015;8(9):15528-15534.

[17] Lin D, Zuo S, Li L, et al. Treatment of neglected femoral neck fractures using the modified dynamic hip screw with autogenous bone and bone morphogenetic protein-2 composite materials grafting. Indian J Orthop. 2015;49(3):342-346.

[18] Zhou L, Yoon SJ, Jang KY, et al. COMP-angiopoietin1 potentiates the effects of bone morphogenic protein-2 on ischemic necrosis of the femoral head in rats. PLoS One. 2014;9(10):e110593.

[19] Kim HK, Aruwajoye O, Du J, et al. Local administration of bone morphogenetic protein-2 and bisphosphonate during non-weight-bearing treatment of ischemic osteonecrosis of the femoral head: an experimental investigation in immature pigs.J Bone Joint Surg Am. 2014;96(18):1515-1524.

[20] Sun W, Li Z, Gao F, et al. Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. PLoS One. 2014;9(6):e100424.

[21] Jiang Y, Zhang Y, Chen W, et al. Achyranthes bidentata extract exerts osteoprotective effects on steroid-induced osteonecrosis of the femoral head in rats by regulating RANKL/RANK/OPG signaling. J Transl Med. 2014;12:334.

[22] Samara S, Dailiana Z, Chassanidis C, et al. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis. Exp Mol Pathol. 2014;96(1):9-14.

[23] Wang JZ, Gao HY, Wang KZ, et al. Effect of Epimedium extract on osteoprotegerin and RANKL mRNA expressions in glucocorticoid-induced femoral head necrosis in rats. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31(10):1714-1717.

[24] 李琪佳,彭晨,梁卫东,等.骨保护素/骨保护素配体在大鼠创伤性股骨头坏死中的表达及意义[J].中国矫形外科杂志,2010,18(1):71-75.

[25] Schmitt-Sody M, Kirchhoff C, Mayer W, et al. Avascular necrosis of the femoral head: inter- and intraobserver variations of Ficat and ARCO classifications. Int Orthop. 2008;32(3):283-287.

[26] Friedrichs K, Gluba S, Eidtmann H, et al. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993;72(12):3641-3647.

[27] Ma XL, Liu ZP, Ma JX, et al. Dynamic expression of Runx2, Osterix and AJ18 in the femoral head of steroid-induced osteonecrosis in rats. Orthop Surg. 2010;2(4):278-284.

[28] ]Xiao G, Jiang D, Thomas P, et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem. 2000; 275: 4453-4459.

[29] de Crombrugghe B, Lefebvre V, Nakashima K. Regulatory mechanisms in the pathways of cartilage and bone formation. Curr Opin Cell Biol. 2001;13: 721-727.